OTHER INFORMATION
+Added: During the quarter ended June 30, 2023, none of our directors or officers (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934) adopted , terminated or modified
+Added: a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K).
EXHIBIT INDEX
Exhibit Description
+Added: Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the Securities and
+Added: Exchange Commission on July 17, 2023).
Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley
12 unchanged sentences
Filed herewith (unless otherwise noted as being furnished herewith)
+Added: Indicates management compensatory plan or arrangement.
Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
PDS Biotechnology Corporation
+Added: August 14, 2023
/s/ Frank Bedu-Addo
−Removed: Frank Bedu-Addo, Ph.D.
+Added: Frank Bedu-Addo
President and Chief Executive Officer
(Principal Executive Officer)
+Added: August 14, 2023
/s/ Matthew Hill
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.